# Open Label RCT for Chronic Severe AR : Entresto vs. CCB/ARB

Study · id `cardio:ct-nct05212597` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05212597](<https://clinicaltrials.gov/study/NCT05212597>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05212597

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT05212597. Randomized; no masking; primary purpose treatment. Start 2022-01-12 (actual); primary completion 2023-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT05212597, source copy `cardio:ctgov-nct05212597-2022-01-28`, retrieved 2026-10-26)
- Started: 2022-01-12 (actual) (ClinicalTrials.gov record NCT05212597, source copy `cardio:ctgov-nct05212597-2022-01-28`, retrieved 2026-10-26)
- Primary completion: 2023-12 (anticipated) (ClinicalTrials.gov record NCT05212597, source copy `cardio:ctgov-nct05212597-2022-01-28`, retrieved 2026-10-26)
- Completion: 2024-12 (anticipated) (ClinicalTrials.gov record NCT05212597, source copy `cardio:ctgov-nct05212597-2022-01-28`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT05212597, source copy `cardio:ctgov-nct05212597-2022-01-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05212597-2022-01-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Open Label RCT for Chronic Severe AR : Entresto vs. CCB/ARB
- Acronym: REVERSE-AR
- Condition: Aortic Valve Insufficiency
- Intervention (Drug): Sacubitril-valsartan
- Intervention (Drug): Amlodipine-losartan
- Lead sponsor: Samsung Medical Center
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Aortic regurgitation (`cardio:aortic-regurgitation`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: Samsung Medical Center (`cardio:org-samsung-medical-center`)

## Provenance

Content hash: 569099b818ead6cbaf51218194d1b41736310a7a9e752ff670cca9e81f713f78
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
